For younger patients with acute myeloid leukemia (AML), an allogeneic transplant from a matched sibling may afford the best chance of cure. In patients who are older or without a matched sibling donor, dose intensification can be achieved with an autologous bone marrow transplant (ABMT). We report here the results of a high-dose chemotherapy regime with nonpurged ABMT in 82 adult patients in first remission of AML with a median follow-up of 31 months. The median age was 40 years (range 16 to 57 years). The median interval between remission and ABMT was 5 months (range 1 to 12 months). Twenty-eight of these patients received a second course of the same URRENT CONVENTIONAL chemotherapy in adults C with acute myeloid leukemia (AML) results in a high remission rate with a subsequent high relapse rate. Several studies have indicated that less than one third of patients obtaining remission are cured of their disease. '-5 This has lead to a search for an effective postremission therapy in AML. The use of maintenance therapy has not been shown to improve leukemia-free survival (LFS).2*6 Single-center studies7 and data from registrie~'.~ have suggested that long-term survival is improved in patients treated in first remission by ablative chemo-radiotherapy and allogeneic bone marrow transplantation, and this has been confirmed recently in prospective comparative studies"-" in which actuarial event-free survivals of approximately 50% have been reported.
high-dose chemotherapy and ABMT. The procedure related mortality rate was 6%. The projected leukemia-free survival (LFS) at 5 years is 48% for all 82 patients and 50%
for the 76 patients with no known preceding myelodysplastic syndrome. For those patients with primary AML who received a double ABMT the projected LFS is 67%. The interval between remission and ABMT did not predict for either relapse or LFS. ABMT using a multidrug chemotherapy protocol is less toxic than allogeneic BMT yet results in a similar LFS. 0 1990 by The American Society of Hematology.
if only offered to those less than 30 years with a matched sibling, will be available to less than 10% of patients with AML.
To extend the role of very intensive consolidation therapy to a wider patient population, autologous bone marrow rescue has been used.I3-l7 Although there is a risk of leukemic contamination of the harvested marrow and there will be no "allogeneic graft-versus-leukemia effect," the morbidity of the procedure is likely to be less than with allografts due to the freedom from problems with either graft-versus-host disease or ongoing immunosuppression.
We report here that patients with AML treated in first remission with high dose chemotherapy and autologous bone marrow transplantation (ABMT) have a similar projected survival to patients treated by allogeneic bone marrow transplantation.
PATIENTS AND METHODS
Eighty-two adult patients have now been treated by our collaborative group using an identical protocol. The median follow-up of this group is 3 1 months with a range between 6 and 110 months. All patients with AML in first complete remission were entered into the program if (1) they gave informed consent; (2) they had a good performance status (Karnofsky greater than 70%); (3) age 16 to 40 years with no HLA-compatible sibling donor or age 41 to 60 years, regardless of donor status. However, it must be noted that because some patients were referred to the transplant centers already in remission, an element of patient selection by the primary physician on other undefined criteria cannot be excluded. There were 38 males and 44 females with a median age of 40 years (range 16 to 57 years).
Four patients were excluded as they were found to be in early relapse at time of assessment for bone marrow harvest, and three patients relapsed after the bone marrow harvest while awaiting the transplant procedure. Six patients had a preceding myelodysplastic state (MDS), which in all cases had progressed to AML at time of commencement of induction therapy.
The patients were all induced with a combination of daunorubicin and cytosine arabinoside normally in combination with 6-thioguanine. The earlier patients received courses of 1 day of daunorubicin at 50 mg/m2 and 5 days of cytosine arabinoside at 100 mg/m2 every 12 hours as per the UK MRC AML eighth trial, while the more recent patients received 3 days of daunorubicin and 10 days of cytosine arabinoside at the same doses again as in the more recent MRC AML ninth trial. Some patients
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48 1 who failed initial induction therapy received second line induction therapy with other agents such as amsacrine, mitozantrone and etoposide. The treatment plan was for patients to receive two consolidation courses with daunorubicin and cytosine arabinoside after the achievement of a complete remission; however, some patients received a different number of consolidation courses, as can he seen in Tables 1 through 3 . The mean number of consolidation courses received was 2.3 with a range from 0 to 6. Sixteen of the 82 patients in this report were previously reported in 1986.13 The median time to achieve remission for the whole group was 51 days (range 20 to 338 days), and the median time from attainment of remission to ABMT was 162 days (range 23 to 365 days). For the patients without a preceding MDS who received a double graft, the median time to achieve remission was 40 days (range 20 to 94 days), and the interval between remission and ABMT was 112 days (range 57 to 277 days). For the patients without a preceding MDS who received a single graft the time to achieve remission was 61 days (range 24 to 369 days), and the time from remission to ABMT was 190 days (range 23 to 365 days).
All patients had a marrow aspirate performed before harvesting to confirm, on morphologic analysis, that they remained in remission. Bone marrow was harvested under general anesthesia and cryopreserved in the manner previously described." No in vitro purging was undertaken. Patients who did not have a Hickman line in situ had one inserted at the time of the harvest. Patients underwent a second bone marrow harvest as soon as possible after recovery from the first procedure was complete.
The high-dose chemotherapy, which was identical in all cases, was BCNU 300 mg/m2 day -5; doxorubicin 50 mg/m2 day -5; cyclophosphamide 1.5 g/m2 day -5 to -3 with mesna 1 to 2 g/g of cyclophosphamide; cytarabine 100 mg/m2 every 12 hours day -5 to -2, and 6-thioguanine 100 mg/m2 every 12 hours day -5 to -2. The autologous marrow was thawed rapidly at the bedside and reinfused on day 0. Patients who achieved satisfactory hematologic regeneration from the first procedure (neutrophils 20.5 x 109/L and unsupported platelet count of 250 x 109/L by Day 42), and in whom there was no contraindication to further intensive therapy, were advised to proceed to a second ABMT as soon as possible after the first with a second cycle of the same high-dose chemotherapy. No posttransplant therapy was administered while patients remained in remission. All patients were treated in single rooms with simple reverse barrier nursing procedures without laminar flow facilities. Blood products were not irradiated and were not screened for cytomegalovirus. Platelets were given prophylactically when the count was below 20 x 109/L. No prophylactic antibiotics were administered during the period of neutropenia, but empirical antibacterial therapy was given for febrile neutropenic episodes.
Statistical analyses were performed by Student's test and chi-squared analysis. Survival curves were drawn by the Kaplan-Meier life table method and compared by the log-rank test. The relationship of clinical features to the outcome of the procedure were analyzed by univariate analysis. Events were included in the analysis up to March 1, 1990 .
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RESULTS
Hematologic recovery. For all 82 patients the median number of days, after the first marrow infusion, to achieve a total neutrophil count of 20.5 x 109/L was 22 (range 11 to 73), and the median number of days to achieve a platelet count of 2 5 0 x 109/L, unsupported by platelet transfusion, was 34 (range 13 to 300). The median number of days after the second ABMT procedure to achieve a total granulocyte count of 20.5 x109/L was 27 (range 12 to 48), and the median number of days to achieve a platelet count of 2 5 0 x 109/L, unsupported by platelet transfusion, was 38 (range 21 to 98). Paired analysis of the times for hematologic recovery after the first and second procedures in the 26 patients who received two grafts showed a highly significant delay for both neutrophil ( P = .004) and platelet recovery ( P = .001) after the second procedure.
There were four procedure-related deaths from the first ABMT procedure (5%), and nine patients relapsed within 90 days of the first procedure. Five of these nine patients who relapsed early had temporally recovered hematologically before their early relapse prevented the second procedure. Of the remaining 69 patients, 54 (78%) achieved full hematologic reconstitution by day 42. These 54 patients were eligible to proceed to the planned second ABMT; however, only 25 of these patients actually received the second cycle of chemotherapy and ABMT, and in addition three patients who had regenerated after day 42 following the first procedure (unique patient Procedure-related morbidity and mortality. All patients developed fever and required antimicrobial therapy. There were no cases of pneumonitis during a first procedure. The causes of the procedure-related deaths that occurred after a first procedure were cerebral hemorrhage (2 cases); hepatorenal failure (l), and aspergillus pneumonia (1). There were two cases of pneumonitis during a second procedure (UPN: UCH 307 and UPN:UCH 323), and both were due to cytomegalovirus and neither was fatal. However, one (UPN: UCH 307) had not recovered normal respiratory function by the time of her death, after relapse, 11 months later. There was a single death after a second procedure due to a varicella pneumonia. Overall, in 110 procedures in 82 patients there have been five procedure-related deaths. Therefore, the risk of a procedure-related death is 4.5% per procedure or 6% overall per patient. There were no cases of graft-versus-host disease despite the fact that random donor platelet and red blood cell transfusions were not irradiated. There has been no long-term morbidity from the procedure, except for the one case referred to previously, and all the survivors have a Karnovsky status of 100%. There has been a single case of late pneumonitis (greater than 3 months) that occurred in a patient who had received a double graft (UPN:UCH245), but this resolved completely with a short course of oral steroid therapy. The cause of this pneumonitis was ascribed to the cumulative dose of BCNU received. There has been no case of cataract in any patient.
The median follow-up for the whole group is 31 months, and a t 5 years the projected overall survival is 53% with a relapse rate of 48% and a projected LFS of 48% (Fig 1) . The outcome in the six patients with a known preceding myelodysplastic state has been poor, with only 2 of Selection of patients for second ABMT.
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6 remaining in remission at 12 months and 28 months post-ABMT. In the 76 patients with an apparently primary disorder at diagnosis, the projected overall survival at 5 years is 55%, with a relapse rate of 47% and a projected LFS of 50% (Fig 2) single graft with rapid hematologic recovery and remained in remission at 90 days was examined. The median interval between grafts in the double-graft group was 90 days. Rapid hematologic recovery was defined as up to 49 days, as this was the latest day on which a patient with primary AML recovered from the first graft and then received a second procedure. However, this comparison single-graft group differed from the double group in that the interval between remission and ABMT was significantly longer (P = .003).
The projected overall survival at 3 years for this group who did not receive the second graft for a nonhematologic reason was 47%, with a projected relapse rate of 60% and a projected LFS of 40%. The difference between these patients who did not receive the second graft for a nonhematologic reason and those who did receive the second graft approaches significance (P = .052) (Fig 3) . Seven patients receiving a double ABMT for primary AML have relapsed, and four of these relapses occurred beyond 1 year from the first ABMT, while only 2 of 14 relapses occurring in the comparison group occurred after 1 year. Prognostic factors for outcome of ABMT that have been analyzed by univariate analysis included age, sex, FrenchAmerican-British (FAB) type, interval from diagnosis to
remission, interval from remission to transplant, and the number of consolidation courses given. No factor was significant in predicting relapse or LFS. In particular, when the patients are divided into two groups, those grafted within 6 months of remission (n = 50) and those grafted between 6 and 12 months into remission (n = 32), there is no significant difference between the two groups in terms of LFS (49% v 46%). If those who only received a single ABMT are analyzed alone there is a small advantage (P = .14) to those receiving ABMT between 6 months and 1 year into remission, but this does not reach significance.
DISCUSSION
The chemotherapy autografting procedure used in this study has resulted in a low early procedure-related mortality (6%) compared with the 20% procedure-related deaths in the first 100 days after allogeneic BMT reported by the Seattle group.' In addition, in allograft recipients there is also a 10% incidence of late procedure-related deaths7 compared with no late nonleukemic deaths after ABMT in this study. There has been almost no significant long-term morbidity from cataracts or pneumonitis observed with this regime, and this contrasts with the sequelae of conventional allografting
"PRIMARY" AML patients n =76
MDS patients n = 6 p is NS. protocols. We believe that the early procedure-related mortality and late morbidity are also reduced when compared with autografting regimes that use total body irradiation (TBI).
Comparisons with autografts using busulphan and cyclophosphamide without TBI are difficult because this has been used mainly in second remission; although in that context it has considerable toxicity, it is not possible to say if this will also be true of its use in first remission. However, the early morbidity with our protocol is considerable compared with conventional therapy as evidenced by the fact that only 41% of patients alive in remission after the first procedure proceeded to the second autograft as originally planned. The rationale of the double-autograft program is based on two premises. Reharvesting of the bone marrow after completion of the first course of chemotherapy when leukemic contamination is likely to be at a nadir effects an in vivo purge, and the two-stage process allows the overall dose of drug that is delivered to be increased without a corresponding increase in toxicity. For three reasons there has been failure to complete the double-graft program in the majority of patients. First, there is a population of patients who relapse early (less than 90 days) after the first graft and who cannot therefore receive the second graft. Second, as regeneration after the second course of intensive chemotherapy is significantly delayed compared with the first, in those cases where recovery from part 1 was slow it was thought unjustified to proceed to a second graft. This selection has kept the procedure-related mortality of the second graft to a minimum but reduced the proportion receiving it. Third, because the first autograft follows intensive induction and consolidation therapy, some patients are unwilling to complete such an arduous treatment program.
The advantage of decreased toxicity compared with allogeneic BMT is balanced by the increased relapse rate seen after ABMT (48% v 25% in the Seattle study of allogeneic BMT in first remission7). However, the projected LFS at 5 years for the two groups is very similar, with an LFS of 48% in this study compared with 45% in a recent report from Seattle" and 48% reported by the International BMT Registry' for allogeneic BMT in AML in first remission. It is, we believe, justifiable to compare these two transplant groups as it is likely that any selection in the two groups will be similar. The favorable comparison of these results with those of allogeneic BMT is underlined by the fact that the age of many of these patients would have put them in a high-risk group for transplant-related complications after allogeneic BMT.',19 They can also be compared favorably with the results of autografting regimes using TBI reported to the European Bone Marrow Transplant Group (EBMT)?'where the LFS at 5 years is 42%. A study of 22 patients from Germany using TBI has reported an LFS of 6195.'' There is an apparent advantage in favor of the use of a double-autograft procedure when patients who received a second procedure are compared with those who did not receive a second graft for a nonhematologic reason, although this does not quite achieve statistical significance (P = .052). Furthermore, it is noteworthy that this group has a significantly shorter remission to transplantation interval than the comparison group. The only definitive way of resolving the value of the second graft would be to randomize patients who are ready to proceed, immediately before the second procedure, to proceed to a second graft or not. This would pose major logistical difficulties.
No in vitro purging procedures, using cyclophosphamide derivatives, were used in this study as we believe that, unlike the situation in the rat model,2' there is no clear in vitro evidence of their selectivity for leukemic cells in human^.^^.*^ The use of these drugs may slow recovery and therefore increase the risk of procedure-related death. Recovery times were observed in this study that were shorter than those reported with regimes using TBI, especially if combined with purged marrow. 14~'5~17. 23 Although hematologic recovery was slower with the second autograft, no patient in remission remained platelet-dependent beyond 100 days, which is not infrequent with purged marrow.14si5*17,23 The most widely quoted evidence that purging may be efficacious in AML autografting comes from retrospective analysis of the EBMT registry,20 which suggests that in a group of patients ablated with cyclophosphamide and TBI, LFS was significantly greater in those patients whose marrow was purged with derivatives of cyclophosphamide and that this advantage was most marked in patients transplanted less than 6 months into remission. This is multicenter data in which some centers performed purging and others did not, and it may be susceptible to differing selection policies. It must also be noted that the excellent results reported by Korbling et all' were obtained with purged marrow.
The key question in this study is whether survival has been improved compared with using conventional chemotherapy alone. Unlike the comparison of transplant series, the effect of selection of patients for transplantation and the effect of the delay between remission and transplantation ("time censoring") needs to be considered when these results are compared with those of conventional chemotherapy. As this group of patients had been in remission for a median of 5 months before ABMT we have compared their outcome to that of patients in the ninth MRC AML trial who maintained first remission for a minimum of 6 months. This shows that compared with the projected LFS of 48% a t 5 years reported here, the projected LFS a t 4 years with conventional therapy in the ninth MRC AML trial of those in remission for a minimum of 6 months is 40%. (R. Gray In conclusion, we have found that ABMT using a multidrug chemotherapy protocol appears less toxic than allogeneic BMT, yet results in a similar LFS. The relatively low mortality and morbidity is particularly important when the use of autografting is extended, as in this study, to patients up to age 60 years, which thus enables intensive therapy to be applied to a much higher proportion of the AML patient population than allogeneic BMT. The results of ABMT compare favorably with conventional consolidation and maintenance therapy, but definitive proof of improved survival must await the outcome of prospective randomized trials.
